Compare BioNano Genomics Inc (BNGO) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Morgan Stanley — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Morgan Stanley trades at $231.03 (market cap $359.10B). The key difference: Morgan Stanley is far larger — about 27204.5× BioNano Genomics Inc's market cap, and Morgan Stanley pays a 1.76% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | MS | |
|---|---|---|
Market Cap | $13.20M | $359.10B |
Sector | Health | Financials |
52-Week High | $4.92 | $228.17 |
52-Week Low | $1.09 | $139.09 |
Enterprise Value | $15.81M | — |
Dividend Yield | — | 1.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Morgan Stanley (MS) trades at $228.17, up 2.65% on the day, with strong bullish momentum from three consecutive quarterly earnings beats. The stock shows robust revenue growth, reaching $66.0B in 2025, and a net income margin of 25.56%. Technical indicators signal a bullish trend, with moving averages supporting upward movement, while RSI levels suggest mixed short-term momentum. Recent news highlights Morgan Stanley's role in leading Anthropic's IPO and expanding AI integration in wealth management, reinforcing its market position.
Outlook remains positive with analyst consensus favoring Buy ratings (53.85%) and a price target of $225.80, slightly below current levels. Key opportunities include continued earnings outperformance and strategic initiatives in AI and IPO leadership. Risks involve volatile cash flows, high debt levels, and macroeconomic sensitivity. Investors should weigh strong fundamentals against execution risks in a dynamic financial landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
